-
Chromosome banding analysis (CBA) of marrow metaphase cells is the standard method to assess response in CML. The authors compared CBA to interphase fluorescence in situ hybridization (I-FISH) in 664 samples where both methods were performed.
-
In a retrospective review of 71 patients treated in either a second- or third-line setting for small-cell lung cancer (SCLC) at a single institution, three orally administered drugs (lomustine, etoposide, and cyclophosphamide) were shown to be effective in producing responses (overall response rate 38%) but had little effect on overall survival (median survival 19 weeks).
-
Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions
-
A 68-year-old white female presented to her internist complaining of fatigue for the past month. The patient is a piano teacher who traveled to her students' houses for their lessons, which had become a significant effort for her.
-
In this review of 195 patients with metastatic breast cancer, detection of 5 or more circulating cancer cells in 7.5 mL of whole blood correlated with reduced overall survival. Furthermore, the presence of extensive bone metastases, as detected by PET/CT, was shown to be associated with increased circulating tumor cells (CTC).
-
-
Among funeral workers, the duration of embalming practice and related formaldehyde exposure were significantly associated with an increased risk for mortality from myeloid leukemia.
-
The authors analyzed data from the Women's Health Initiative (WHI) combined Estrogen/Progestin Trial to determine if new-onset breast tenderness (NOBT) was associated with the development of breast cancer.
-
In the last two months, there were four articles in the American Journal of Obstetrics & Gynecology and Obstetrics & Gynecology dealing with drugs that are commonly used in pregnancy and their possible contribution to adverse outcomes. One of these articles was particularly attention-getting.
-
In this issue: Two oral medications for relapsing-remitting MS in phase III development; antihypertensives find new uses; Ginkgo biloba does not prevent cognitive decline in elderly; and FDA Actions.